NCT01897038 2016-11-02A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular CarcinomaHoffmann-La RochePhase 1 Completed9 enrolled